In a recent trial that aimed to evaluate the differential effects of trastuzumab and lapatinib under low and normal PTEN conditions in HER2-overexpressing breast cancer cell lines, lapatinib was effective and decreased both pMAPK and pAKT under low PTEN conditions. Here, PTEN is linked to breast cancer.